SIRT1 Regulation Modulates Stroke Outcome

Translational Stroke Research

Volumn 4, Issue 6, 2013, Pages 663-671

  Petegnief, Valérie ^a   Planas, Anna M ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Cerebral ischemia; Endogenous neuroprotection; Histone deacetylase; Sirtuin; Stress protein

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE ACETATE; BRAIN DERIVED NEUROTROPHIC FACTOR; ENTINOSTAT; FIBROBLAST GROWTH FACTOR 2; GLUCOSE; GLUCOSE REGULATED PROTEIN 78; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERLEUKIN 12; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROSTAGLANDIN E2; PROTEIN P53; RESVERATROL; SIRTINOL; SIRTUIN 1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 2;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AUTOPHAGY; BRAIN ISCHEMIA; CALORIC RESTRICTION; CELL DEATH; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CHROMATIN STRUCTURE; DEACETYLATION; ENDOPLASMIC RETICULUM STRESS; ENERGY YIELD; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXCITOTOXICITY; GENE OVEREXPRESSION; GENE SILENCING; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HISTONE ACETYLATION; HUMAN; HUNTINGTON CHOREA; HYPOXIC ISCHEMIC ENCEPHALOPATHY; MIDDLE CEREBRAL ARTERY OCCLUSION; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR LOCALIZATION SIGNAL; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; UNFOLDED PROTEIN RESPONSE; WALLERIAN DEGENERATION;

ALZHEIMER DISEASE; ANIMALS; BRAIN ISCHEMIA; CELL DEATH; CELL SURVIVAL; HUMANS; HUNTINGTON DISEASE; PARKINSON DISEASE; SIRTUIN 1; STROKE;

EID: 84888294444     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-013-0277-y     Document Type: Review

References (84)

1. Brand D, Ratan R. Epigenetics and the environment: In Search of the "toleroasome" vital to execution of ischemic preconditioning. Transl Stroke Res. 2013;4(1): 56-62.
2. Fu Y, Sun JL, Ma JF, Geng X, Sun J, Liu JR, et al. The neuroprotection of prodromal transient ischaemic attack on cerebral infarction. Eur J Neurol. 2008;15(8): 797-801.
3. Schaller B. Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance. Neurosci Lett. 2005;377(3): 206-11.
4. Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer. 2010;10(12): 819-23.
5. Imai S-i, Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharm Sci. 2010;31(5): 212-20.
6. Rajendran R, Garva R, Krstic-Demonacos M, Demonacos C. Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. J Biomed Biotechnol. 2011;2011: 1-17.
7. Chuang D-M, Leng Y, Marinova Z, Kim H-J, Chiu C-T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32(11): 591-601.
8. Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, Faller DV, et al. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci. 2010;6(6): 599-612.
9. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem. 2007;282(9): 6823-32.
10. Jin Q, Yan T, Ge X, Sun C, Shi X, Zhai Q. Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol. 2007;213(1): 88-97.
11. Yang X-J, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell. 2008;31(4): 449-61.
12. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell. 2004;16(1): 93-105.
13. Morris KC, Lin HW, Thompson JW, Perez-Pinzon MA. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J Cereb Blood Flow Metab. 2011;31(4): 1003-19.
14. Yi J, Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta. 2010;1804(8): 1684-89.
15. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004;305(5682): 390-92.
16. Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell. 2007;6(6): 759-67.
17. Arumugam TV, Phillips TM, Cheng A, Morrell CH, Mattson MP, Wan R. Age and energy intake interact to modify cell stress pathways and stroke outcome. Ann Neurol. 2010;67(1): 41-52.
18. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6): 493-506.
19. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA. 2007;104(17): 7217-22.
20. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458(7241): 1056-60.
21. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303(5666): 2011-15.
22. Giannakou ME, Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol. 2004;14(8): 408-12.
23. Hasegawa K, Yoshikawa K. Necdin regulates p53 acetylation via sirtuin1 to modulate DNA damage response in cortical neurons. J Neurosci. 2008;28(35): 8772-84.
24. Lanzillotta A, Pignataro G, Branca C, Cuomo O, Sarnico I, Benarese M, et al. Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window. Neurobiol Dis. 2013;49: 177-89.
25. Yan W, Fang Z, Yang Q, Dong H, Lu Y, Lei C, et al. SirT1 mediates hyperbaric oxygen preconditioning-induced ischemic tolerance in rat brain. J Cereb Blood Flow Metab. 2013;33(3): 396-406.
26. Pfister JA, Ma C, Morrison BE, D'Mello SR. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PloS One. 2008;3(12): e4090.
27. Yao H, Rahman I. Perspectives on translational and therapeutic aspects of SIRT1 in inflammaging and senescence. Biochem Pharm. 2012;84(10): 1332-39.
28. Kong S, McBurney MW, Fang D. Sirtuin 1 in immune regulation and autoimmunity. Immunol Cell Biol. 2012;90(1): 6-13.
29. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-[kappa]B-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23(12): 2369-80.
30. Zong Y, Sun L, Liu B, Deng Y-S, Zhan D, Chen Y-L, et al. Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264. 7 Macrophage Cells. PLoS One. 2012;7(8).
31. Yang H, Zhang W, Pan H, Feldser HG, Lainez E, Miller C, et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. PloS One. 2012;7(9): e46364.
32. Bellet MM, Sassone-Corsi P. Mammalian circadian clock and metabolism-the epigenetic link. J Cell Sci. 2010;123: 3837-48.
33. Hisahara S, Chiba S, Matsumoto H, Tanno M, Yagi H, Shimohama S, et al. Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci USA. 2008;105(40): 15599-604.
34. Ramadori G, Lee CE, Bookout AL, Lee S, Williams KW, Anderson J, et al. Brain SIRT1: anatomical distribution and regulation by energy availability. J Neurosci. 2008;28(40): 9989-96.
35. Kumar R, Chaterjee P, Sharma PK, Singh AK, Gupta A, Gill K, et al. Sirtuin1: a promising serum protein marker for early detection of Alzheimer's disease. PloS One. 2013;8(4): 1-e61560.
36. Donmez G. The neurobiology of sirtuins and their role in neurodegeneration. Trends Pharm Sci. 2012;33(9): 494-501.
37. Hung C-W, Chen Y-C, Hsieh W-L, Chiou S-H, Kao C-L. Ageing and neurodegenerative diseases. Ageing Res Rev. 2010;9: S36-46.
38. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 Suppresses β-amyloid production by activating the α-secretase gene ADAM10. Cell. 2010;142(2): 320-32.
39. Min S-W, Cho S-H, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67(6): 953-66.
40. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet. 2005;37(4): 349-50.
41. Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med. 2012;18(1): 159-65.
42. Jiang M, Wang J, Fu J, Du L, Jeong H, West T, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med. 2012;18(1): 153-58.
43. Donmez G, Arun A, Chung C-Y, McLean PJ, Lindquist S, Guarente L. SIRT1 Protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci. 2012;32(1): 124-32.
44. Kakefuda K, Fujita Y, Oyagi A, Hyakkoku K, Kojima T, Umemura K, et al. Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection. Biochem Biophys Res Commun. 2009;387(4): 784-88.
45. Park G, Jeong J-W, Kim J-E. SIRT1 deficiency attenuates MPP+-induced apoptosis in dopaminergic cells. FEBS Lett. 2011;585(1): 219-24.
46. Faraco G, Pancani T, Formentini L, Mascagni P, Fossati G, Leoni F, et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharm. 2006;70(6): 1876-84.
47. Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler J-P, Boutillier A-L. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 2003;22(24): 6537-49.
48. Kim SH, Lu HF, Alano CC. Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PloS One. 2011;6(3): 1-e14731.
49. Ren M, Leng Y, Jeong M, Leeds PR, Chuang D-M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem. 2004;89(6): 1358-67.
50. Marinova Z, Ren M, Wendland JR, Leng Y, Liang M-H, Yasuda S, et al. Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem. 2009;111(4): 976-87.
51. Lanzillotta A, Sarnico I, Ingrassia R, Boroni F, Branca C, Benarese M, et al. The acetylation of RelA in Lys310 dictates the NF-[kappa]B-dependent response in post-ischemic injury. Cell Death Dis. 2010;1: e96.
52. Liu D, Gharavi R, Pitta M, Gleichmann M, Mattson MP. Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. Neuromol Med. 2009;11(1): 28-42.
53. Wang L, Wang Y, Cui M, Luo W, Wang X, Barber P, et al. A dietary polyphenol resveratrol acts to provide neuroprotection in recurrent stroke models by regulating AMPK and SIRT1 signaling, thereby reducing energy requirements during ischemia. Eur J Neurosci 2013: 1-13.
54. Raval AP, Dave KR, Perez-Pinzon MA. Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab. 2005;26(9): 1141-47.
55. Della-Morte D, Dave KR, DeFazio RA, Bao YC, Raval AP, Perez-Pinzon MA. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience. 2009;159(3): 993-1002.
56. Liu D, Pitta M, Mattson MP. Preventing NAD+ depletion protects neurons against excitotoxicity. Ann N Y Acad Sci. 2008;1147(1): 275-82.
57. Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β cells. PloS Biol. 2006;4(2): e31.
58. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science. 2004;305(5686): 1010-13.
59. Li X-h, Chen C, Tu Y, Sun H-t, Zhao M-l, Cheng S-x, et al. Sirt1 promotes axonogenesis by deacetylation of Akt and inactivation of GSK3. Mol Neurobiol. 2013: 1-10.
60. Abdellatif M. Sirtuins and Pyridine Nucleotides. Circ Res. 2012;111(5): 642-56.
61. Wang P, Xu T-Y, Guan Y-F, Tian W-W, Viollet B, Rui Y-C, et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol. 2011;69(2): 360-74.
62. Wang P, Guan Y-F, Du H, Zhai Q-W, Su D-F, Miao C-Y. Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy. 2012;8(1): 77-87.
63. Jeong J-K, Moon M-H, Lee Y-J, Seol J-W, Park S-Y. Autophagy induced by the class III histone deacetylase Sirt1 prevents prion peptide neurotoxicity. Neurobiol Aging. 2013;34(1): 146-56.
64. Guo W, Qian L, Zhang J, Zhang W, Morrison A, Hayes P, et al. Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling. J Neurosci Res. 2011;89(11): 1723-36.
65. Li Y, Yokota T, Gama V, Yoshida T, Gomez JA, Ishikawa K, et al. Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation. Cell Death Differ. 2007;14(12): 2058-67.
66. Kim GW, Noshita N, Sugawara T, Chan PH. Early decrease in DNA repair proteins, Ku70 and Ku86, and subsequent DNA fragmentation after transient focal cerebral ischemia in mice. Stroke. 2001;32(6): 1401-07.
67. Chelluboina B, Klopfenstein JD, Gujrati M, Rao JS, Veeravalli KK. Temporal regulation of apoptotic and anti-apoptotic molecules after middle cerebral artery occlusion followed by reperfusion. Mol Neurobiol. 2013.
68. Li Y, Chopp M, Zhang ZG, Zaloga C, Niewenhuis L, Gautam S. p53-immunoreactive protein and p53 mRNA expression after transient middle cerebral artery occlusion in rats. Stroke. 1994;25(4): 849-55.
69. Leker RR, Aharonowiz M, Greig NH, Ovadia H. The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin α. Exp Neurol. 2004;187(2): 478-86.
70. Shi H. Hypoxia inducible factor 1 as a therapeutic target in ischemic stroke. Curr Med Chem. 2009;16(34): 4593-600.
71. Ma Y, Zechariah A, Qu Y, Hermann DM. Effects of vascular endothelial growth factor in ischemic stroke. J Neurosci Res. 2012;90(10): 1873-82.
72. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell. 2010;38(6): 864-78.
73. Laemmle A, Lechleiter A, Roh V, Schwarz C, Portmann S, Furer C, et al. Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1alpha protein under hypoxic conditions. PloS One. 2012;7(3): e33433.
74. Wang FM, Chen YJ, Ouyang HJ. Regulation of unfolded protein response modulator XBP1s by acetylation and deacetylation. Biochem J. 2010;433(1): 245-52.
75. Ghosh HS, McBurney M, Robbins PD. SIRT1 negatively regulates the mammalian target of rapamycin. PloS One. 2010;5(2): e9199.
76. Hermann DM, Kilic E, Hata R, Hossmann KA, Mies G. Relationship between metabolic dysfunctions, gene responses and delayed cell death after mild focal cerebral ischemia in mice. Neuroscience. 2001;104(4): 947-55.
77. MartíndelaVega C, Burda J, Nemethova M, Quevedo C, Alcázar A, Martín ME, et al. Possible mechanisms involved in the down-regulation of translation during transient global ischaemia in the rat brain. Biochem J. 2001;357(3): 819-26.
78. Petegnief V, Font-nieves M, Martín ME, Salinas M, Planas AM. Nitric oxide mediates NMDA-induced persistent inhibition of protein synthesis through dephosphorylation of eukaryotic initiation factor 4E-binding protein 1 and eukaryotic initiation factor 4G proteolysis. Biochem J. 2008;411(3): 667-77.
79. Li Y, Xu W, McBurney MW, Longo VD. SirT1 Inhibition Reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab. 2008;8(1): 38-48.
80. Sansone L, Reali V, Pellegrini L, Villanova L, Aventaggiato M, Marfe G, et al. SIRT1 silencing confers neuroprotection through IGF-1 pathway activation. J Cell Physiol. 2013;228(8): 1754-61.
81. Milner J. Cellular regulation of SIRT1. Curr Pharm Des. 2009;15(1): 39-44.
82. Naqvi A, Hoffman TA, DeRicco J, Kumar A, Kim CS, Jung SB, et al. A single-nucleotide variation in a p53-binding site affects nutrient-sensitive human SIRT1 expression. Hum Mol Genet. 2010;19(21): 4123-33.
83. Flachsbart F, Croucher PJ, Nikolaus S, Hampe J, Cordes C, Schreiber S, et al. Sirtuin 1 (SIRT1) sequence variation is not associated with exceptional human longevity. Exp Gerontol. 2006;41(1): 98-102.
84. Kuningas M, Putters M, Westendorp RG, Slagboom PE, van Heemst D. SIRT1 gene, age-related diseases, and mortality: the Leiden 85-plus study. J Gerontol A: Biol Med Sci. 2007;62(9): 960-5.